Relay Therapeutics Inc (RLAY)

$7.53

-0.03

(-0.4%)

Market is closed - opens 7 PM, 23 May 2024

Insights on Relay Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, -1.0K → 10.00M (in $), with an average increase of 100.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -83.49M → -81.38M (in $), with an average increase of 2.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 90.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 307.4%

Performance

  • $7.30
    $7.81
    $7.53
    downward going graph

    3.05%

    Downside

    Day's Volatility :6.53%

    Upside

    3.59%

    downward going graph
  • $5.70
    $13.32
    $7.53
    downward going graph

    24.3%

    Downside

    52 Weeks Volatility :57.21%

    Upside

    43.47%

    downward going graph

Returns

PeriodRelay Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-28.48%
-0.6%
0.0%
6 Months
-6.32%
12.1%
0.0%
1 Year
-31.89%
11.3%
0.0%
3 Years
-75.81%
17.6%
-20.1%

Highlights

Market Capitalization
864.2M
Book Value
$5.64
Earnings Per Share (EPS)
-2.63
Wall Street Target Price
21.96
Profit Margin
0.0%
Operating Margin TTM
-921.31%
Return On Assets TTM
-24.58%
Return On Equity TTM
-40.4%
Revenue TTM
35.3M
Revenue Per Share TTM
0.28
Quarterly Revenue Growth YOY
4327.900000000001%
Gross Profit TTM
1.4M
EBITDA
-364.0M
Diluted Eps TTM
-2.63
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.82
EPS Estimate Next Year
-2.85
EPS Estimate Current Quarter
-0.71
EPS Estimate Next Quarter
-0.74

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Relay Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 191.63%

Current $7.53
Target $21.96

Technicals Summary

Sell

Neutral

Buy

Relay Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Relay Therapeutics Inc
Relay Therapeutics Inc
27.06%
-6.32%
-31.89%
-75.81%
-78.43%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Relay Therapeutics Inc
Relay Therapeutics Inc
NA
NA
NA
-2.82
-0.4
-0.25
NA
5.64
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Relay Therapeutics Inc
Relay Therapeutics Inc
Buy
$864.2M
-78.43%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • SB INVESTMENT ADVISERS (UK) LTD

    21.02%
  • Vanguard Group Inc

    8.02%
  • BlackRock Inc

    7.21%
  • T. Rowe Price Associates, Inc.

    6.46%
  • Casdin Capital, LLC

    5.57%
  • JPMorgan Chase & Co

    4.57%

Corporate Announcements

  • Relay Therapeutics Inc Earnings

    Relay Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate

Organization
Relay Therapeutics Inc
Employees
309
CEO
Mr. Alexis A. Borisy A.M.
Industry
Health Technology

FAQs